WEKO3
アイテム
Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats
https://repository.lib.tottori-u.ac.jp/records/7391
https://repository.lib.tottori-u.ac.jp/records/739110258cfe-f2de-4034-b9e4-cf659f803f91
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
vp110_31.pdf (2.0 MB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2022-09-08 | |||||
| タイトル | ||||||
| タイトル | Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Cardiopulmonary remodeling | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Pulmonary arterial hypertension | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Right ventricular hypertrophy | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Sorafenib | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | Toceranib | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Cardiopulmonary remodeling | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Pulmonary arterial hypertension | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Right ventricular hypertrophy | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Sorafenib | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Toceranib | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| 著者 |
日笠, 喜朗
× 日笠, 喜朗× Leong, Zi Ping |
|||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | The United Graduate School of Veterinary Science, Yamaguchi University | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | The United Graduate School of Veterinary Science, Yamaguchi University / Joint Department of Veterinary Medicine, Laboratory of Veterinary Internal Medicine, Tottori University | |||||
| 抄録 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Sorafenib reverses pulmonary arterial hypertension (PAH) and cardiopulmonary remodeling (CPR), but the effects of toceranib are unknown. This study investigated anti-remodeling effects and determined optimal doses of toceranib and sorafenib on monocrotaline (MCT)-induced PAH and CPR in rats. MCT-treated rats were orally treated with a 14-day course of sorafenib (10, 30, or 100 mg/kg), toceranib (1, 3, or 10 mg/kg), or water. Both sorafenib and toceranib significantly reversed the right ventricular (RV) hypertrophy at 10 mg/kg, but only sorafenib significantly improved the RV systolic and mean pressures. Sorafenib significantly normalized the B-type natriuretic peptide mRNA level of the RV and increased the non-muscularized pulmonary artery percentage. However, these effects were only observed at the highest toceranib dose, and neither toceranib dose reduced the fully muscularized pulmonary artery percentage. Further, the inhibition on vascular endothelial growth factor (VEGF) signaling was stronger in sorafenib than in toceranib. Besides the stronger inhibition on mitogen-activated protein kinase signaling, the greater reversal ability of sorafenib may be also due to the simultaneous blockade on the C-X-C chemokine receptor type 4 and autophagy induction. Toceranib insignificantly reversed CPR, and a high-dose therapy did not improve the RV hemodynamic outcomes. Sorafenib significantly reversed CPR, and a low-dose sorafenib therapy may be a suitable therapeutic agent for PAH. | |||||
| 書誌情報 |
Vascular Pharmacology en : Vascular Pharmacology 巻 110, p. 31-41, 発行日 2018-11-30 |
|||||
| 出版者 | ||||||
| 出版者 | Elsevier | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 15371891 | |||||
| DOI | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1016/j.vph.2018.07.002 | |||||
| 権利 | ||||||
| 権利情報 | (C) 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/ | |||||
| 情報源 | ||||||
| 関連名称 | Leong, Zi Ping. Hikasa, Yoshiaki. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats. Vascular Pharmacology. 110. 31-41. 2018. doi:10.1016/j.vph.2018.07.002 | |||||
| 関連サイト | ||||||
| 識別子タイプ | URI | |||||
| 関連識別子 | https://www.sciencedirect.com/science/article/pii/S1537189118302192 | |||||
| 関連名称 | https://www.sciencedirect.com/science/article/pii/S1537189118302192 | |||||
| 著者版フラグ | ||||||
| 出版タイプ | AM | |||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
